News

July 6, 2016 4:00 pm
Janssen Inc. announces Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX™ (daratumumab) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a...
July 6, 2016 4:00 pm
The Committee for Medicinal Products for Human Use (CHMP)—a division of the European Medicines Agency—recommended a change to the terms of the marketing authorization for Kyprolis® (carfilzomib) for the treatment of relapsed multiple myeloma. As of...

Pages